



**BioAlliance Pharma ranked as France's fastest growing company
in the 2009 Deloitte Technology Fast 50™**

Paris, November 19, 2009 – BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that it has won first prize in Deloitte's Technology Fast 50 2009™ ranking of France's fastest-growth technology companies.

The ranking is drawn up according to turnover growth over the fiscal years 2004 to 2008. During this period, BioAlliance Pharma's earnings grew 70-fold to reach €8.2 million.

This strong growth is due to the success of Loramyc® (indicated for the treatment of oral candidiasis in immunocompromised patients), the first product to be developed by BioAlliance Pharma and launched on the French market. Loramyc® has already received marketing authorizations in 12 European countries and is going through the registration process in the United States. BioAlliance Pharma has already signed Loramyc® industrial partnerships in the United States and South-East Asia.

"Today, BioAlliance Pharma is in a unique position to leverage its assets and innovation skills and keep on growing. Our assets are based around Setofilm® (a second supportive care product that we expect to market in 2010) and positive Phase III clinical trial results for another product administered through mucosal route (in the treatment of oro-facial herpes)", commented Dominique Costantini, President and CEO of BioAlliance Pharma. "We are delighted to have topped the Deloitte ranking, which acknowledges our ability to go from bench to market and transform innovations into medically proven products with added value for patients."

"Inclusion in the Deloitte Technology Fast 50™ means being one of France's leaders in terms of five-year growth and demonstrates exceptional qualities in today's highly competitive technology markets", added Eric Morgain, partner in charge of the Technology Fast 50™ program at Deloitte. "We heartily congratulate BioAlliance Pharma on being one of France's fastest-growing technology companies".

About BioAlliance Pharma

As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops and markets innovative products in France, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs.

For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com.

About the Technology Fast 50™ program

The Technology Fast 50 Award was created in 1995 in San Jose, California, (in the heart of Silicon Valley) and soon spread to the whole of the United States and then the United Kingdom, Canada, the Netherlands, Israel and France. The program is now operating in more than 40 countries and regions around the world. It was created to highlight the exceptional contribution of technology companies to economic growth.

About Deloitte France

Deloitte musters diverse skills and competencies to provide a wide range of services to client companies of all sizes and from all sectors – from big multinationals and medium-sized companies to very small local firms. The 6,000 staff and partners embody the company's dynamism and success by their commitment to customers and their constant focus on the excellence of the services they provide. Deloitte France's services included audit, consultancy, risk services, fiscal & legal work, accounting and corporate finance in line with Deloitte's multidisciplinary strategy and ethical professional standards. In France, Deloitte S.A. is a member of Deloitte Touche Tohmatsu, whose business services are provided by its subsidiaries and affiliates. For more information, visit www.deloitte.fr.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma S.A.'s website (<http://www.bioalliancepharma.com>).

BioAlliance Pharma SA

Dominique Costantini, President du Directoire

Tel.: +33 1 45 58 76 01

dominique.costantini@bioalliancepharma.com

Nicolas Fellmann, Directeur Financier

Tel.: +33 1 45 58 71 00

nicolas.fellmann@bioalliancepharma.com

ALIZE RP

Caroline Carmagnol

Tel.: +33 6 64 18 99 59

caroline@alizerp.com